壓瘡治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球壓瘡治療市場規模達74億美元，預計2034年將以5.9%的複合年成長率成長，達到131億美元。人口老化是推動這一成長的主要因素，尤其是在已開發國家。在這些國家，行動不便和長期不活動會增加壓瘡的風險。隨著年齡的成長，人們更容易出現阻礙活動的情況，進而引發壓瘡。此外，肥胖和糖尿病等生活方式相關疾病的盛行率不斷上升，這兩種疾病都會減緩傷口癒合，進一步推動了對有效傷口護理療法的需求。慢性病發病率的上升導致臨床上難癒合傷口的病例增多，這刺激了對能夠改善患者預後的先進治療方法的需求。

傷口護理解決方案的持續技術發展也推動了市場發展。智慧傷口敷料、生物活性產品和現代治療系統等創新技術正在透過縮短癒合時間並提高患者舒適度，徹底改變壓瘡管理。由於這些解決方案在處理複雜傷口方面效果顯著，在醫院和家庭護理環境中的應用日益廣泛。人們對早期介入和預防策略益處的認知不斷提高，正在鼓勵更多患者和醫療保健提供者選擇先進的產品。來自政府醫療保健計畫（尤其是在北美和歐洲）的支持也推動了這些產品的採用。報銷計畫和臨床指引也強化了人們對實證傷口照護方法的偏好。

壓瘡治療涵蓋一系列旨在預防和治癒壓力性皮膚損傷的醫療解決方案。這些潰瘍，也稱為褥瘡或褥瘡，通常發生在行動不便的患者身上。治療的目標是緩解壓力、促進組織修復、預防感染並改善患者整體健康。治療方案包括專用敷料、生物製劑、治療設備和專為傷口護理設計的藥劑。隨著臨床關注點轉向改善癒合效果，結合多種療法的綜合治療方法在市場上日益普及。

在關鍵產品類別中，傷口治療設備在2024年成為表現最佳的細分市場，估值達33億美元，預計2034年將成長至57億美元，複合年成長率為5.7%。這些設備包含有助於加速傷口癒合、降低感染風險和最大程度減輕患者不適的技術。這些設備在醫院和門診環境中的使用日益增多，凸顯了人們日益依賴先進技術來更有效地管理複雜傷口。壓力管理系統和自動化傷口監測的最新進展進一步增強了該細分市場的功能，使其在臨床上得到更廣泛的應用。

就產品類型而言，處方藥領域在2024年佔據領先地位，預計到2034年將達到35億美元。這種主導地位可以歸因於處方療法的更高療效，以及在治療重症病例時需要規範干預的醫療需求。此類產品包括先進的外用製劑和用於治療更複雜或慢性傷口的全身療法。隨著醫療保健提供者越來越青睞基於患者需求的個人化治療方案，預計處方藥領域將在未來幾年保持領先。

按最終用途分類，醫院在2024年佔據了最大的市場佔有率，達到43.8%，預計到2034年將創造55億美元的收入。醫院憑藉其完善的基礎設施、經驗豐富的醫務人員以及專業的傷口護理科室，仍然是治療壓瘡（尤其晚期壓瘡）的主要中心。行動不便或有潛在健康問題的患者更有可能尋求醫院的治療，因為醫院可以有效地運用多學科方法。此外，醫院通常是需要外科手術或重症監護的患者的第一接診點。

從區域來看，北美地區以2024年29億美元的收入引領全球市場，預計2034年將達到50億美元，複合年成長率為5.5%。這一領先地位得益於其完善的醫療保健體系、對尖端傷口護理技術的早期採用以及對臨床研發的大量投入。該地區老年人口的不斷成長以及肥胖和糖尿病等併發症的高發病率，使得先進的治療方案成為必要。此外，優惠的報銷方案和強而有力的監管也使得創新療法得以有序推廣。

領先企業透過廣泛的產品組合、策略性研發投入和全球佈局不斷鞏固其地位。主要參與者正在積極開發先進的傷口管理解決方案，並擴大其在新興經濟體的影響力。合併、授權協議和產品發布等競爭策略在塑造產業格局方面發揮著至關重要的作用。新創公司和小型企業也透過專注於專業生物製劑和客製化護理方案來開拓利基市場，從而加快了行業創新的步伐。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 慢性病盛行率上升
    • 傷口護理技術日益進步
    • 提高認知和預防保健措施
    • 老年人口不斷增加
  • 產業陷阱與挑戰
    • 治療費用高
  • 市場機會
    • 擴大居家傷口管理
    • 不斷成長的研發投入與活動
• 成長潛力分析
• 技術格局
• 監管格局
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係和合作
  • 擴張計劃

第5章：市場估計與預測：按產品，2021 年至 2034 年

• 主要趨勢
• 傷口護理敷料
  • 藻酸鹽敷料
  • 泡棉敷料
  • 水膠體敷料
  • 水凝膠敷料
  • 薄膜敷料
  • 其他傷口護理敷料
• 生物製劑
  • 皮膚替代品
  • 生長因子
  • 其他生物製劑
• 傷口治療設備
  • 負壓傷口治療
  • 高壓氧治療
  • 其他傷口治療設備
• 藥物
• 其他產品

第6章：市場估計與預測：按潰瘍分期，2021 年至 2034 年

• 主要趨勢
• 第一階段
• 第 2 階段
• 第 3 階段
• 第四階段

第7章：市場估計與預測：按類型，2021 年至 2034 年

• 主要趨勢
• 場外交易（OTC）
• 處方

第8章：市場估計與預測：按年齡層，2021 年至 2034 年

• 主要趨勢
• 兒科
• 成人
• 老年

第9章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院
• 門診手術中心（ASC）
• 專科診所
• 其他最終用途

第10章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：公司簡介

• 3M Healthcare
• AHA Hyperbarics
• Integra LifeSciences
• Ascend Laboratories
• B. Braun
• Baxter
• BioTissue
• Cardinal Health
• Coloplast
• Convatec
• Ethicon (Johnson and Johnson)
• GlaxoSmithKline (GSK)
• Ipca Laboratories
• LifeNet Health
• Medline
• MIMEDX
• Molnlycke Health Care
• Organogenesis
• Pfizer
• Smith & Nephew
• StimLabs
• Zimmer Biomet

The Global Pressure Ulcers Treatment Market was valued at USD 7.4 billion in 2024 and is estimated to grow at a CAGR of 5.9% to reach USD 13.1 billion by 2034. A major contributor to this growth is the aging population, particularly in developed nations, where limited mobility and prolonged immobility increase the risk of pressure ulcers. As individuals age, they are more likely to develop conditions that hinder movement, leading to the development of pressure sores. Additionally, the rising prevalence of lifestyle-related diseases such as obesity and diabetes-both of which are known to slow wound healing-further drives demand for effective wound care therapies. The growing incidence of chronic illnesses is translating into increased clinical cases of non-healing wounds, spurring the demand for sophisticated treatment approaches that improve patient outcomes.

The market is also benefiting from ongoing technological developments in wound care solutions. Innovations such as smart wound dressings, biologically active products, and modern therapy systems are revolutionizing pressure ulcer management by reducing healing time and improving comfort for patients. These solutions are increasingly adopted across both hospital settings and homecare environments due to their effectiveness in managing complex wounds. Greater awareness about early intervention and the benefits of preventive strategies is encouraging more patients and healthcare providers to opt for advanced products. Support from government healthcare programs, particularly in North America and Europe, is also bolstering adoption. Reimbursement schemes and clinical guidelines are reinforcing the preference for evidence-based wound care methods.

Pressure ulcer treatment encompasses a range of medical solutions aimed at preventing and healing pressure-induced skin injuries. These ulcers, also referred to as bedsores or decubitus ulcers, generally occur in patients with limited mobility. The goal of treatment is to relieve pressure, promote tissue recovery, prevent infection, and enhance overall patient health. Therapeutic options include specialized dressings, biologics, therapy devices, and pharmaceutical agents designed for wound care. As clinical attention shifts toward improving healing outcomes, integrated treatment approaches that combine multiple therapies are gaining ground in the market.

Among the key product categories, wound therapy devices emerged as the top-performing segment in 2024 with a valuation of USD 3.3 billion and are projected to grow to USD 5.7 billion by 2034, registering a CAGR of 5.7%. These devices include technologies that support faster healing, reduce infection risk, and minimize patient discomfort. Their increasing use in hospitals and outpatient settings highlights the growing reliance on advanced technology to manage complex wounds more efficiently. Recent improvements in pressure management systems and automated wound monitoring are further enhancing the capabilities of this segment, leading to broader clinical adoption.

In terms of type, the prescription segment led in 2024 and is estimated to reach USD 3.5 billion by 2034. This dominance can be attributed to the higher efficacy of prescription therapies and the medical necessity for regulated interventions in treating severe cases. Products in this category include advanced topical formulations and systemic therapies that are prescribed for more complex or chronic wounds. As healthcare providers increasingly favor personalized treatment plans based on patient needs, the prescription category is expected to maintain its lead over the coming years.

By end use, hospitals represented the largest share of the market in 2024, accounting for 43.8%, and are projected to generate USD 5.5 billion in revenue by 2034. Hospitals remain the primary centers for treating pressure ulcers, particularly in advanced stages, owing to their comprehensive infrastructure, availability of skilled medical staff, and specialized departments for wound care. Patients with limited mobility or underlying health issues are more likely to seek hospital-based care where multidisciplinary approaches can be deployed effectively. Additionally, hospitals are often the first point of contact for patients requiring surgical intervention or intensive care.

Regionally, North America led the global market with a revenue of USD 2.9 billion in 2024 and is expected to reach USD 5 billion by 2034, growing at a CAGR of 5.5%. This leadership is supported by a well-established healthcare framework, early adoption of cutting-edge wound care technologies, and substantial investment in clinical research and development. The rising number of elderly individuals and the high prevalence of comorbid conditions such as obesity and diabetes in the region make advanced treatment solutions a necessity. Furthermore, favorable reimbursement scenarios and strong regulatory oversight have enabled a structured rollout of innovative therapies.

Leading companies continue to strengthen their positions through extensive product portfolios, strategic R&D investment, and global reach. Major participants are actively developing advanced wound management solutions and expanding their presence in emerging economies. Competitive strategies such as mergers, licensing agreements, and product launches are playing a vital role in shaping the landscape. Startups and smaller firms are also carving out a niche by focusing on specialized biologics and customizable care options, intensifying the pace of innovation within the industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Product
  • 2.2.3 Ulcer stage
  • 2.2.4 Type
  • 2.2.5 Age group
  • 2.2.6 End use
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic disease
    • 3.2.1.2 Growing advancement in wound care technologies
    • 3.2.1.3 Increasing awareness and preventive care measures
    • 3.2.1.4 Growing geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expanding homecare-based wound management
    • 3.2.3.2 Growing R&D investment and activities
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Key developments
  • 4.5.1 Mergers and acquisitions
  • 4.5.2 Partnerships and collaborations
  • 4.5.3 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Wound care dressings
  • 5.2.1 Alginate dressings
  • 5.2.2 Foam dressings
  • 5.2.3 Hydrocolloid dressings
  • 5.2.4 Hydrogel dressings
  • 5.2.5 Film dressings
  • 5.2.6 Other wound care dressings
• 5.3 Biologics
  • 5.3.1 Skin substitutes
  • 5.3.2 Growth factors
  • 5.3.3 Other biologics
• 5.4 Wound therapy devices
  • 5.4.1 Negative pressure wound therapy
  • 5.4.2 Hyperbaric oxygen therapy
  • 5.4.3 Other wound therapy devices
• 5.5 Medications
• 5.6 Other products

Chapter 6 Market Estimates and Forecast, By Ulcer Stage, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Stage 1
• 6.3 Stage 2
• 6.4 Stage 3
• 6.5 Stage 4

Chapter 7 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Over-the-counter (OTC)
• 7.3 Prescription

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Pediatric
• 8.3 Adult
• 8.4 Geriatric

Chapter 9 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Ambulatory surgical centers (ASCs)
• 9.4 Specialty clinics
• 9.5 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 3M Healthcare
• 11.2 AHA Hyperbarics
• 11.3 Integra LifeSciences
• 11.4 Ascend Laboratories
• 11.5 B. Braun
• 11.6 Baxter
• 11.7 BioTissue
• 11.8 Cardinal Health
• 11.9 Coloplast
• 11.10 Convatec
• 11.11 Ethicon (Johnson and Johnson)
• 11.12 GlaxoSmithKline (GSK)
• 11.13 Ipca Laboratories
• 11.14 LifeNet Health
• 11.15 Medline
• 11.16 MIMEDX
• 11.17 Molnlycke Health Care
• 11.18 Organogenesis
• 11.19 Pfizer
• 11.20 Smith & Nephew
• 11.21 StimLabs
• 11.22 Zimmer Biomet